Zhu H, Xu X, Fang X, et al. - Researchers assessed the efficacy as well as the safety of long‐term antithrombotic strategies in patients suffering from chronic coronary syndrome, by performing a network meta‐analysis. They analyzed four randomized studies. As per findings of network meta‐analysis, relative to aspirin monotherapy, the odds ratios for trial‐defined major adverse cardiovascular and cerebrovascular events were estimated to be 0.86, 0.89, 0.74, and 0.72 for ticagrelor plus aspirin, rivaroxaban monotherapy, rivaroxaban plus aspirin, and for thienopyridine plus aspirin, respectively. Overall, significant decrease in the incidence of major adverse cardiovascular and cerebrovascular events was conferred by all antithrombotic strategies combined with aspirin but these raised the risk of major bleeding relative to aspirin monotherapy. For patients having chronic coronary syndrome and high‐risk factors, rivaroxaban plus aspirin seemed to be the preferred long‐term antithrombotic regimen in the light of the outcomes of all ischemic and bleeding events and all‐cause mortality.